Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Amcenestrant 400 mg	34
Overall Study	STARTED	Amcenestrant 200 mg	36
Overall Study	STARTED	Letrozole 2.5 mg	35
Overall Study	Treated	Amcenestrant 400 mg	33
Overall Study	Treated	Amcenestrant 200 mg	36
Overall Study	Treated	Letrozole 2.5 mg	35
Overall Study	COMPLETED	Amcenestrant 400 mg	33
Overall Study	COMPLETED	Amcenestrant 200 mg	36
Overall Study	COMPLETED	Letrozole 2.5 mg	35
Overall Study	NOT COMPLETED	Amcenestrant 400 mg	1
Overall Study	NOT COMPLETED	Amcenestrant 200 mg	0
Overall Study	NOT COMPLETED	Letrozole 2.5 mg	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04191382/flow